New Pyrrolopyrimidines as LRRK2 Inhibitors for Treating Parkinson's Disease

This patent describes the novel pyrroloppyrimidine compounds as LRRK2 kinase inhibitors. The patent includes the synthesis of compounds, compositions containing them and their use in the treatment of or prevention of diseases associated with LRRK2 kinase activity, such as Parkinson's disease, A...

Full description

Saved in:
Bibliographic Details
Published inCurrent medicinal chemistry Vol. 31; no. 33; p. 5477
Main Author De, Surya K
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2024
Subjects
Humans
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - antagonists & inhibitors
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - metabolism
Parkinson Disease - drug therapy
Parkinson Disease - metabolism
Patents as Topic
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Pyrimidines - chemistry
Pyrimidines - pharmacology
Pyrimidines - therapeutic use
Pyrroles - chemistry
Pyrroles - pharmacology
Pyrroles - therapeutic use
Pyrrolopyrimidines
mutation of LRRK2
LRRK2 kinase
Alzheimer's disease
amyotrophic lateral sclerosis (ALS)
Parkinson’s disease
Online AccessGet more information

Cover

More Information
Summary:This patent describes the novel pyrroloppyrimidine compounds as LRRK2 kinase inhibitors. The patent includes the synthesis of compounds, compositions containing them and their use in the treatment of or prevention of diseases associated with LRRK2 kinase activity, such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
ISSN:1875-533X
DOI:10.2174/0929867331666230821101247